Add Presentation to Slide Tray Presentation:
Treatment for Hepatitis C Virus Infection in Adults: Comparative Effectiveness
Authors: Stephen C. Pappas, MD, JD
Background: Uncertainties Related to the Treatment of Chronic Hepatitis C Virus Infection in Adults
Decisions about treatment strategies for patients with chronic hepatitis C virus (HCV) infection who are treatment naïve are based on various factors, including:
- Disease-related factors such as hepatitis C genotype, the presence of liver disease, and the severity of liver disease
- Patient-related factors such as the presence of comorbidities and demographic characteristics
- The continued development of new treatment strategies, including the testing of the all-oral interferon-sparing therapies that may be available in the coming years
- An understanding of the comparative benefits and harms of dual and triple antiviral treatment regimens and whether they are affected by medication dose, treatment duration, and dosing strategy (fixed treatment vs. response-guided therapy), which is particularly important, given the availability of new treatment options (telaprevir and boceprevir) for chronic HCV infections
- Chou R, Hartung D, Rahman B, et al. Treatment for Hepatitis C Virus Infection in Adults: A Comparative Effectiveness Review. Evidence Report No. 76 (Prepared by the Oregon Evidence-based Practice Center under Contract No. 290-2007-10057-I). Rockville, MD: Agency for Healthcare Research and Quality; August 2012. AHRQ Publication No. 12-EHC113-EF. Available at www.effectivehealthcare.ahrq.gov/hepctreatment.cfm.
Your slide tray is being processed.